Difference between revisions of "Editing test page"
Jump to navigation
Jump to search
m (Replaced content with "==Carboplatin & Paclitaxel (CP) & Nivolumab {{#subobject:3a6hg7|Regimen=1}}== CP & Nivolumab: '''<u>C</u>'''arboplatin, '''<u>P</u>'''aclitaxel, Nivolumab <div class="tocc...") Tag: Replaced |
|||
| (23 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | ==Carboplatin & | + | ==Carboplatin & Paclitaxel (CP) & Nivolumab {{#subobject:3a6hg7|Regimen=1}}== |
| − | + | CP & Nivolumab: '''<u>C</u>'''arboplatin, '''<u>P</u>'''aclitaxel, Nivolumab | |
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
| − | ===Regimen variant #1, | + | ===Regimen variant #1, 5/175/360 {{#subobject:59hhq7|Variant=1}}=== |
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
| Line 10: | Line 10: | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
| − | |[https:// | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844511/ Forde et al. 2022 (CheckMate 816)] |
| − | | | + | {| class="wikitable" style="margin:auto; color:black; background-color:#d3d3d3" |
| − | |style="background-color:#1a9851"|Phase 3 ( | + | |[[File:HopeAI.png|link=https://hemonc.org|alt=Alt text|Title=text|frameless|150px|center]] |
| − | |1a. [[# | + | |- |
| − | | style="background-color:# | + | |Click to learn more! |
| + | |- | ||
| + | |} | ||
| + | |2017-2019 | ||
| + | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) | ||
| + | |1a. [[#Carboplatin_.26_Paclitaxel_.28CP.29|CP]]<br>1b. [[#Cisplatin_.26_Vinorelbine_.28CVb.29|CVb]]<br>1c. [[#Cisplatin_.26_Docetaxel_.28DC.29|DC]] | ||
| + | | style="background-color:#1a9850" |Superior EFS (co-primary endpoint)<br>Median EFS: 31.6 vs 20.8 mo<br>(HR 0.63, 97.38% CI 0.43-0.91)<br><br>Superior pCR rate (co-primary endpoint)<br>pCR rate: 24% vs 2.2%<br>(OR 13.94, 99% CI 3.49-55.75) | ||
|- | |- | ||
|} | |} | ||
| − | + | ''Note: there were additional comparator options depending on histology; see the respective histology-specific pages for more details.'' | |
| − | + | <div class="toccolours" style="background-color:#fdcdac"> | |
| − | + | ====Biomarker eligibility criteria==== | |
| − | + | *CheckMate 816: No sensitizing EGFR or ALK mutations | |
| − | |||
| − | '' | ||
| − | |||
| − | <div class="toccolours" style="background-color:# | ||
| − | ==== | ||
| − | * | ||
</div></div> | </div></div> | ||
Latest revision as of 12:58, 18 July 2024
Carboplatin & Paclitaxel (CP) & Nivolumab
CP & Nivolumab: Carboplatin, Paclitaxel, Nivolumab
Regimen variant #1, 5/175/360
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy | ||
|---|---|---|---|---|---|---|
Forde et al. 2022 (CheckMate 816)
|
2017-2019 | Phase 3 (E-RT-esc) | 1a. CP 1b. CVb 1c. DC |
Superior EFS (co-primary endpoint) Median EFS: 31.6 vs 20.8 mo (HR 0.63, 97.38% CI 0.43-0.91) Superior pCR rate (co-primary endpoint) pCR rate: 24% vs 2.2% (OR 13.94, 99% CI 3.49-55.75) |
Note: there were additional comparator options depending on histology; see the respective histology-specific pages for more details.
Biomarker eligibility criteria
- CheckMate 816: No sensitizing EGFR or ALK mutations